Biotech Values

[jfmcrr]

Any idea whether drug companies can get updates during trials or are they completely walled off? Brian mentioned being “blinded” to the study during a call. Do you know when they are allowed to see data/make a decision to add a cohort?

The classic "Double Blind" study has a Data and Safety Monitoring committee and this is the sole entity that is unblinded to the ongoing results. This is the gold standard for the scientific method and the most preferred paradigm.

I got into this a decade ago on the AMRN ihub board over what can constitute an acceptable experimental design regarding blinded vs unblinded studies, statistics and the need for "classic" experimental design. I think this is one of the references I cited; https://events-support.com/Documents/Yao.pdf .

It depends. There can be a certain amount of hack and slash to get to a certain point if it is part of the the original proposal and approved/done in a controlled manner. This is more acceptable early in the process. And circumstances dictate

Also all my education, thought processes and experience is superannuated because I am. But I believe in the end a "classic" double blind trial will happen in this instance because there is no reason it can't.